More positive data boosts Spinraza efficacy claims

25 April 2017

American biotech company Biogen (Nasdaq: BIIB) has announced it will present more data from its Phase III Spinraza (nusinersen) study, which reveal an even greater improvement in motor function in children with spinal muscular atrophy (SMA) than previously shown.

The data will be presented at the annual meeting of the American Academy of Neurology, currently taking place in Boston, USA.

The company says the overall findings of the study also show a favorable safety profile for the drug, which was approved by the US Food and Drug Administration late last year, for the treatment of SMA in certain pediatric and adult patients.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK